Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study

Outcomes for children with relapsed or refractory acute myeloid leukaemia remain poor. The BCL-2 inhibitor, venetoclax, has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older adults for whom chemotherapy is not suitable with newly diagnosed acute mye...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The lancet oncology Ročník 21; číslo 4; s. 551 - 560
Hlavní autoři:	Karol, Seth E, Alexander, Thomas B, Budhraja, Amit, Pounds, Stanley B, Canavera, Kristin, Wang, Lei, Wolf, Joshua, Klco, Jeffery M, Mead, Paul E, Das Gupta, Soumyasri, Kim, Su Y, Salem, Ahmed Hamed, Palenski, Tammy, Lacayo, Norman J, Pui, Ching-Hon, Opferman, Joseph T, Rubnitz, Jeffrey E
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.04.2020 Elsevier Limited
Témata:	Acute myeloid leukemia Adolescent Antineoplastic Combined Chemotherapy Protocols - administration & dosage Bcl-2 protein Bone marrow Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Chemotherapy Child Child, Preschool Children Colitis Cytarabine Cytarabine - administration & dosage Female Fungal infections Hematology Hematology, Oncology, and Palliative Medicine Humans Idarubicin - administration & dosage Intravenous administration Invasiveness Leukemia Leukemia, Myeloid, Acute - drug therapy Male Neoplasm Recurrence, Local - drug therapy Neutropenia Neutrophils Patients Remission Sepsis Stem cells Sulfonamides - administration & dosage Transplants & implants Young Adult United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!